Sawai Group Holdings Co., Ltd. (TYO:4887)

Market Cap	194.94B -14.3%
Revenue (ttm)	201.68B +6.7%
Net Income	10.44B -12.8%
EPS	81.52 -15.3%
Shares Out	115.49M
PE Ratio	18.73
Forward PE	10.26
Dividend	56.00 (3.27%)
Ex-Dividend Date	Mar 30, 2026

Volume	118,100
Open	1,694.50
Previous Close	1,688.00
Day's Range	1,688.00 - 1,716.50
52-Week Range	1,664.50 - 2,447.00
Beta	0.03
Analysts	Buy
Price Target	2,477.78 (+45.11%)
Earnings Date	May 15, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 3,310
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4887

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.

Analyst Summary

According to 9 analysts, the average rating for 4887 stock is "Buy." The 12-month stock price target is ¥2,478, which is an increase of 45.11% from the latest price.

Price Target

¥2,478

(45.11% upside)

Analyst Consensus: Buy